Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04863950 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 27, 2025 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 2026 to Aug 2026
    • Study completion date: Sep 2026 to Nov 2026
    v8
  2. Primary completion date: Sep 2024 to Feb 2026
    • Study completion date: Sep 2025 to Sep 2026
    v7
  3. Primary completion date: Sep 2023 to Sep 2024
    • Study completion date: Sep 2024 to Sep 2025
    v6
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2022 to May 25, 2022
    v5
  5. Start date: Feb 2022 to Jun 2022
    • Eligibility criteria shortened, about 7 words
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Nov 2021 to Feb 2022v3
  2. Start date: Sep 16, 2021 to Nov 2021
    • Primary completion date: Sep 16, 2023 to Sep 2023
    • Study completion date: Sep 16, 2024 to Sep 2024
    • Study title shortened, about 3 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
Trial Details
NCT Number NCT04863950
Lead Sponsor The University of Texas Health Science Center at San Antonio
Conditions
(from sponsor)		 Glioblastoma
Related terms Glioblastoma
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov